Small molecule · Inhibitor of protein arginine methyltransferase 5 (PRMT5) (PRMT5) · developed by Tango Therapeutics
TNG456 is an orally bioavailable, blood-brain-barrier penetrant small molecule that selectively inhibits PRMT5 bound to methylthioadenosine (MTA), acting specifically in MTAP-deleted cancer cells. By reducing methylation of arginine residues on histone and non-histone proteins, it alters gene expression that governs cell proliferation. It is studied in non-small cell lung cancer, glioblastoma and other solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06810544 | Phase 1/2 | Non Small Cell Lung Cancer | Recruiting | TNGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Brain TumorGlioma Glioblastoma MultiformeGlioma, MalignantLung CancerNon Small Cell Lung CancerNon-Small Cell AdenocarcinomaSolid Tumor
Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.
See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TNGX catalysts and pipeline →